Long-term oral administration of dipyridamole improves both cardiac and physical status in patients with mild to moderate chronic heart failure: A prospective open-randomized study

Hypertension Research

Volumn 30, Issue 10, 2007, Pages 913-919

  Sanada, Shoji ^a,b   Asanuma, Hiroshi ^c   Koretsune, Yukihiro ^d   Watanabe, Kouki ^e   Nanto, Shinsuke ^f   Awata, Nobuhisa ^g   Hoki, Noritake ^b   Fukunami, Masatake ^b   Kitakaze, Masafumi ^c   Hori, Masatsugu ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA GENERAL MEDICAL CENTER   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^d OSAKA NATIONAL HOSPITAL   (Japan)

^e Saiseikai Saijo Hospital   (Japan)

^f KANSAI ROSAI HOSPITAL   (Japan)

^g OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Adenosine; Dipyridamole; Exercise; Heart failure; Natriuretic peptide

Indexed keywords

ALDOSTERONE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EXPOSURE; ECHOCARDIOGRAPHY; EXERCISE TOLERANCE; FEMALE; FOLLOW UP; HEART FAILURE; HEART FUNCTION TEST; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE SIZE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LONG TERM CARE; MALE; MEAN ARTERIAL PRESSURE; OPEN STUDY; OUTPATIENT CARE; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VALVULAR HEART DISEASE;

AGED; DIPYRIDAMOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; EXERCISE; EXERCISE TEST; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; VASODILATOR AGENTS;

EID: 36249025555     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.913     Document Type: Article

References (24)

1. Packer M: Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure. Eur Heart J 1995; 16 (Suppl F): 4-6.
2. Vatner DE, Asai K, Iwase M, et al: Beta-adrenergic receptor-G protein-adenylyl cyclase signal transduction in the failing heart. Am J Cardiol 1999; 83: 80H-85H.
3. Mehra MR, Uber PA, Potluri S: Renin-angiotensin-aldosterone and adrenergic modulation in chronic heart failure: contemporary concepts. Am J Med Sci 2002; 324: 267-275.
4. Cicoira M, Kalra PR, Anker SD: Growth hormone resistance in chronic heart failure and its therapeutic implications. J Card Fail 2003; 9: 219-226.
5. Aukrust P, Gullestad L, Ueland T, Damas JK, Yndestad A: Inflammatory and anti-inflanimatory cytokines in chronic heart failure: potential therapeutic implications. Ann Med 2005; 37:74-85.
6. Packer M: Current role of beta-adrenergic blockers in the management of chronic heart failure. Am J Med 2001; 110 (Suppl7A):81S-94S.
7. Yan AT, Yan RT, Liu PP: Narrative review: pharmacotherapy for chronic heart failure: evidence from recent clinical trials. Ann Intern Med 2005; 142: 132-145.
8. Funaya H, Kitakaze M, Node K, Minamino T, Komamura K, Hori M: Plasma adenosine levels increase in patients with chronic heart failure. Circulation 1997; 95: 1363-1365.
9. Hori M, Kitakaze M: Adenosine, the heart, and coronary circulation. Hypertension 1991; 18: 565-574.
10. Lagerkranser N, Sollevi A, Irestedt L, Tidgren B, Andreen M: Renin release during controlled hypotension with sodium nitroprusside, nitroglycerin and adenosine: a comparative study in the dog. Acta Anaesthesiol Scand 1985; 29: 45-49.
11. Bouma MG, Wildenberg FAJM, Buurman WA: Adenosine inhibits cytokine release and expression adhesion molecules by activated human endothelial cells. Am J Physiol 1996; 270: C522-C529.
12. Kitakaze M, Minamino T, Node K, et al: Elevation of plasma adenosine levels may attenuate the severity of chronic heart failure. Cardiovasc Drugs Ther 1998; 12: 307-309.
13. Richards AM, Lainchbury JG, Nicholls MG, Troughton RW, Yandle TG: BNP in hormone-guided treatment of heart failure. Trends Endocrinol Metab 2002; 13: 151-155.
14. Tsutamoto T, Wada A, Maeda K, et al: Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-516.
15. Omland T, Aakvaag A, Bonarjee VV, et al: Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term suvival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996; 93: 1963-1969.
16. Koitabashi T, Inomata T, Niwano S, et al: Distinguishable optimal levels of plasma B-type natriuretic peptide in heart failure management based on complicated atrial fibrillation. Int Heart J 2005; 46: 453-464.
17. Berger R, Huelsman M, Strecker K, et al: B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105: 2392-2397.
18. Yazaki Y, Muhlestein JB, Carlquist JF, et al: A common variant of the AMPD1 gene predicts improved survival in patients with ischemic left ventricular dysfunction. J Card Fail 2004; 10: 316-320.
19. Loh E, Rebbeck TR, Mahoney PD, DeNofrio D, Swain JL, Holmes EW: Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure. Circulation 1999; 99: 1422-1425.
20. Kalsi KK, Yuen AH, Rybakowska IM, et al: Decreased cardiac activity of AMP deaminase in subjects with the AMPD1 mutation - a potential mechanism of protection in heart failure. Cardiovasc Res 2003; 59: 678-684.
21. Liao Y, Takashima S, Asano, Y, et al: Activation of adenosine A1 receptor attenuates cardiac hypertrophy and prevents heart failure in murine left ventricular pressure-overload model. Circ Res 2003; 93: 759-766.
22. Zhang Q, Moalem J, Tse J, Scholz PM, Weiss HR: Effects of natriuretic peptides on ventricular myocyte contraction and role of cyclic GMP signaling. Eur J Pharmacol 2005; 510: 209-215.
23. Imaizumi S, Miura S, Nishikawa H, et al: Angiotensin II type 1 receptor blockers do not promote coronary collateral circulation in patients with coronary artery disease. Hypertens Res 2006; 29: 135-141.
24. Laghi-Pasini F, Guideri F, Petersen C, et al: Blunted increase in plasma adenosine levels following dipyridamole stress in dilated cardiomyopathy patients. J Intern Med 2003; 254:591-596.